neurologic signs or symptoms. These may include problems with thinking, balance, eyesight, weakness on 1 side of your body, strength, or using your arms or legs (see accompanying Patient Information). o Hepatitis B virus (HBV) reactivation: Before starting treatment with OCREVUS, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with OCREVUS. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving OCREVUS. o Weakened immune system: OCREVUS taken before or after other medicines that weaken the immune system could increase your risk of getting infections. What are the possible side effects of OCREVUS? OCREVUS may cause serious side effects, including: • Risk of cancers (malignancies) including breast cancer. Follow your healthcare provider’s instructions about standard screening guidelines for breast cancer. Most common side effects include infusion-related reactions and infections. These are not all the possible side effects of OCREVUS. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For additional Important Safety Information, please see accompanying Patient Information. ©2017 Genentech USA, Inc. All rights reserved. OCR/090616/0283 9/17 VisitOCREVUS.comorcall1-844-627-3887tolearnmore. *In two 2-year clinical studies vs REBIF. † REBIF® is a registered trademark of EMD Serono, Inc. ‡ First dose of OCREVUS is split—given as 2 separate infusions 2 weeks apart. In relapsing MS, OCREVUS was consistently proven superior to REBIF®,*† a commonly used treatment. OCREVUS demonstrated: • Reduction of relapses • Slowing of disability progression • Significant impact on brain lesions In primary progressive MS, OCREVUS is the first and only treatment proven effective. OCREVUS is given every 6 months.‡ Ask your healthcare provider about OCREVUS. In relapsing MS, OCREVUS was consistently proven In primary progressive MS, OCREVUS is Have fewer maybes with OCREVUS. For people with relapsing or primary progressive forms of multiple sclerosis (MS) MS